Expanding frontiers, transforming cancer treatment

Your day–by–day guide to ASCO
3 – 7 June 2011

McCormick Place Convention Center
Chicago, Illinois, USA
Congress site plan
# Key presentations

<table>
<thead>
<tr>
<th>Product key</th>
<th>Product name</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Avastin</td>
</tr>
<tr>
<td>H</td>
<td>Herceptin</td>
</tr>
<tr>
<td>M</td>
<td>MetMAb</td>
</tr>
<tr>
<td>R</td>
<td>Rituxan/MabThera</td>
</tr>
<tr>
<td>T</td>
<td>Tarceva</td>
</tr>
<tr>
<td>V</td>
<td>Vemurafenib</td>
</tr>
<tr>
<td>X</td>
<td>Xeloda</td>
</tr>
</tbody>
</table>
POSTER DISCUSSION SESSION

Session: Gynecologic Cancer

Time: 14:00 - 18:00
Venue: E450a

Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC). (Robert A. Burger, Poster: 12)

Poster discussion: 17:00 - 18:00

Avastin  Herceptin  MetMAb  Rituxan/MabThera

Tarceva  Vemurafenib  Xeloda
**GENERAL POSTER SESSION**

**Session: Gastrointestinal (Noncolorectal) Cancer**

*Time: 08:00 - 12:00*

*Venue: Hall A*

Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC). (Yoon-Koo Kang, Poster: 37E)

**ORAL ABSTRACT SESSION**

**Session: Gastrointestinal (Colorectal) Cancer**

*Time: 13:00 - 16:00*

*Venue: Hall D1*

Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. (Carmen J. Allegra)

**Presentation time: 14:30**

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (Thierry Andre)

**Presentation time: 15:00**
GENERAL POSTER SESSION

Session: Lung Cancer - Metastatic/Non-small Cell

Time: 14:00 - 16:00
Venue: Hall A

AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data. (Fabrice Barlesi, Poster: 35B)

POSTER DISCUSSION SESSION

Session: Tumor Biology

Time: 14:00 - 18:00
Venue: S103

Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor Vemurafenib (V) in metastatic melanoma. (Kenneth J. Bloom, Poster: 15)

Poster discussion: 17:00 - 18:00
ORAL ABSTRACT SESSION

Session: Gynecologic Cancer

Time: 15:00 - 18:00
Venue: E354a

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. (Gunnar Kristensen)

Presentation time: 16:00

OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (Carol Aghajanian)

Presentation time: 16:15
ORAL ABSTRACT SESSION

Session: Lung Cancer - Metastatic/Non-small Cell

Time: 09:30 - 12:30
Venue: Hall D1

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. (Rafael Rosell)

Presentation time: 09:30

Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (Michael Thomas)

Presentation time: 09:45

Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. (David R. Spigel)

Presentation time: 10:00

PLENARY SESSION

Session: Science of Oncology Award and Lecture

Time: 13:00 - 16:00
Venue: Hall B1

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (Paul B. Chapman)

Presentation time: 15:15
POSTER DISCUSSION SESSION

Session: Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell

Time: 08:00 - 12:00
Venue: E450a

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). (Heather A. Wakelee, Poster: 7)

Poster discussion: 11:30 - 12:30

Session: Gastrointestinal (Colorectal) Cancer

Time: 08:00 - 12:00
Venue: E450b

A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). (Anders Johnsson, Poster: 15)

Poster discussion: 11:30 - 12:30

Session: Melanoma/Skin Cancers

Time: 08:00 - 12:00
Venue: S403

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (Mario E. Lacouture, Poster: 8)

Poster discussion: 11:30 - 12:30
ORAL ABSTRACT SESSION

Session: Breast Cancer - Triple-negative/Cytotoxics/Local Therapy

Time: 09:30 - 12:30
Venue: Hall B1

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (Harry D. Bear)
Presentation time: 10:15

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). (Bernd Gerber)
Presentation time: 10:30

Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (Adam Brufsky)
Presentation time: 12:00
GENERAL POSTER SESSION

Session: Leukemia, Myelodysplasia, and Transplantation

Time: 13:00 - 17:00
Venue: Hall B1

A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. (Francesca R. Mauro, Poster: 42B)

Session: Breast Cancer - HER2/ER

Time: 13:00 - 17:00
Venue: Hall A

Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer. (Istvan Lang, Poster: 6A)

First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC. (Sergei Tjulandin, Poster: 5E)

Session: Breast Cancer - Triple-negative/Cytotoxics/Local Therapy

Time: 13:00 - 17:00
Venue: Hall A

Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC). (Peter Klare, Poster: 19D)
Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120). (Yoshinori Ito, Poster: 24D)

Session: Lymphoma and Plasma Cell Disorders

Time: 13:00 - 17:00
Venue: Hall A

Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices. (Ajay K. Nooka, Poster: 43H)

CLINICAL SCIENCE SYMPOSIUM

Session: BRAF: From Biology to Patients

Time: 13:15 - 14:45
Venue: E354b

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts). (Grant A. McArthur)

Presentation time: 14:00
POSTER DISCUSSION SESSION

Session: Lung Cancer - Metastatic/Non-small

Time: 14:00 - 18:00
Venue: E450a

Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer. (Caicun Zhou, Poster: 9)

Poster discussion: 17:00 - 18:00

Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib ± MetMAb in patients with advanced non-small-cell lung cancer (NSCLC). (Wei Yu, Poster: 18)

Poster discussion: 17:00 - 18:00
POSTER DISCUSSION SESSION

Session: Genitourinary (Nonprostate) Cancer

Time: 08:00 - 12:00
Venue: E450b

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Bohuslav Melichar, Poster: 1)

Poster discussion: 11:30 - 12:30

ORAL ABSTRACT SESSION

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 09:30 - 12:30
Venue: Hall D1

Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial. (Yung-Jue Bang)

Presentation time: 10:15
Hotels

A Chicago Marriott Downtown Magnificent Mile
540 North Michigan Ave.
(Driveway entrance on 541 North Rush Street)
Chicago, IL, 60611
Phone: +1 312 836 0100
Fax: +1 312 836 6139
Breakfast: Harvest Grill Restaurant, 2nd floor
06:30 - 11:00

B Hyatt Regency McCormick Place
2233 S. Martin L. King Dr.
Chicago, IL, 60616
Phone: +1 312 567 1234
Fax: +1 312 528 4000
Breakfast: Restaurant Shore
06:30 - 11:00

C Hilton Chicago
720 South Michigan Ave.
Chicago, IL, 60605
Phone: +1 312 922 4400
Fax: +1 312 922 5240
Breakfast: Restaurant Pavilion
Mon - Fri 06:00 - 11:00
Sat - Sun 06:00 - 12:00

D The James Hotel
55 East Ontario
Chicago, IL, 60611
Phone: +1 312 337 1000
Fax: +1 312 337 7217
Breakfast: Primehouse Restaurant
06:30 - 09:30
Swissôtel Chicago
323 East Wacker Dr.
Chicago, IL, 60601-9722
Phone: + 1 312 565 0565
Fax: + 1 312 565 0540
Breakfast: Restaurant Geneva
06:30 - 10:30

Conrad Hilton
521 North Rush St.
Chicago, IL, 60611
Phone: + 1 312 645 1500
Breakfast: Restaurant at Conrad
06:30 - 11:30

W Lake Shore
644 N Lake Shore Dr.
Chicago, IL, 60611
Phone: + 1 312 943 9200
Breakfast: ALTITUDE, 33rd Floor
06:30 - 10:30